The final agenda for the Chronic Total Occlusion and Left Main Summit has been set and is now available at: http://www.
The three-day conference will feature state-of-the-art technologies, research findings and new developments in therapeutic procedures essential for interventional cardiologists to optimize success in chronic total coronary occlusions and left main coronary interventions. Topics at this year's summit will include:
- Fundamentals of CTO PCI
- Complex Retrograde and Antegrade CTO PCI
- Updates on Global CTO Registries
- Left Main PCI: Essential Knowledge
- Left Main Publications and Abstracts
- Complication Prevention and Management
- How to Improve Outcomes
- Live Case Transmissions
- Edited Taped Case Presentations
A complete blockage in the coronary artery lasting more than three months, or chronic total occlusion (CTO), has historically been one of the most challenging types of blockages to treat with an interventional procedure. Leading practitioners of percutaneous coronary intervention (PCI) must become experts at restoring blood flow for patients with chronic total occlusions, and with advanced techniques, success rates greater than 90% may be obtained.
Stenting of the unprotected left main coronary artery has also emerged as a viable alternative to surgery in selected patients but requires a special skill set and understanding of anatomy, imaging, hemodynamic support, and adjunctive devices.
This year's conference will emphasize both advanced techniques and evidence-based medicine, along with live case transmissions featuring the world's leading experts in left main and CTO stenting.
February 21-23, 2013
New York Marriott Marquis Hotel
New York, NY
HOW TO REGISTER:
Media may apply for registration by emailing firstname.lastname@example.org.
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine.